Biotech VC Funds

CV Ventures is a venture capital firm founded in 2013 with a dual base in Hong Kong and Chicago. The firm invests in life science and fintech ventures across Asia and the United States, bridging capital from Western financial markets with opportunities in the Asian technology ecosystem. Operating across the medical and biotech, fintech, education, and real estate sectors, CV Ventures targets startups and more mature businesses across North America and Asia-Pacific. The fund deploys checks of $250,000 to $5 million at seed and Series A stages, led by a two-partner team based in the United States. Portfolio companies include Gini, a fintech platform, and the Model UN Development Organization in the education sector, reflecting the fund's range across technology and mission-driven businesses. With 5 investments across healthtech, fintech, education, and related categories, CV Ventures has operated as a highly selective vehicle focused on cross-border opportunities that benefit from the firm's Hong Kong-Chicago network. CV Ventures occupies a niche defined by its geographic bridge between Asian and North American markets — a position that requires genuine operational credibility in both regions. The fund's current status is listed as inactive, though its portfolio represents a selective body of work across the life sciences and fintech sectors that sit at the intersection of the firm's two home markets.

CyberAgent Capital (CAC) is a prominent venture capital firm specializing in early-stage investments, particularly in internet and technology-based startups. Founded in 2006 as part of the larger CyberAgent Group, the firm focuses on companies in the seed and early-growth stages. With a strong global network, CAC operates across key markets in Asia, including Japan, China, Taiwan, Indonesia, Vietnam, and Thailand, offering startups a bridge to regional and global expansion. The firm’s investment philosophy centers on incubating and accelerating internet-based businesses. CAC provides deep strategic and operational support, particularly in user acquisition, UI/UX design, and marketing strategies. This hands-on approach allows startups to leverage CAC’s extensive industry knowledge and its connection to the CyberAgent Group, fostering quicker growth in fast-moving markets​. CyberAgent Capital typically invests in startups aiming for global reach and scalability, helping them expand across borders. The firm manages several funds and offers flexible investment sizes depending on the growth stage, supporting companies from the initial idea phase to market expansion​. Some of CAC’s notable portfolio companies include Tokopedia, Coda Payments, and Viddsee, which highlight the firm’s successful track record in backing high-potential tech-driven ventures​.

Cybernetix Ventures is a venture capital firm focused on investing in early-stage robotics, automation, and artificial intelligence (AI) startups. Based in Boston, the firm invests globally, targeting companies that apply innovative automation technologies across various industries. Their portfolio includes cutting-edge startups such as Raise Robotics, which develops robots to improve safety and efficiency on construction sites, and Realtime Robotics, which creates processors for rapid, collision-free robot movements in unstructured environments. Cybernetix’s investment strategy focuses on companies in sectors like healthcare, industrial automation, and construction, aiming to revolutionize traditional industries through robotics and AI. Other notable portfolio companies include Kewazo, which offers robotic solutions to streamline construction processes, and Bionomous, which combines AI and micro-engineering to automate biological entity sorting, a breakthrough for healthcare labs. The firm is led by experienced partners like Mark Martin, who brings over 25 years of leadership in industrial and tech sectors. Cybernetix Ventures is known for its deep engagement with its portfolio companies, providing strategic support alongside capital to drive scalable growth in the rapidly evolving world of automation and robotics.

Cycle Capital, founded in 2009 and headquartered in Montreal, Quebec, is a venture capital firm that specializes in investing in early-stage cleantech companies. The firm aims to support businesses that are developing innovative technologies to create a sustainable future. Cycle Capital manages over CAD 600 million through various funds, targeting sectors such as renewable energy, smart grid technology, energy storage, green chemicals, and advanced materials. The firm's portfolio includes a wide range of companies focused on sustainable innovations. Notable investments include Rhombus Energy Solutions, which develops bi-directional electric vehicle charging infrastructure; Bus.com, an online bus reservation platform; and Airex Energy, which transforms biomass into biochar and biocoal. Other significant investments are in GreenMantra Technologies, which converts waste plastics into specialty polymer additives, and Mysa, which creates smart thermostats for electric HVAC systems. Cycle Capital has also achieved several successful exits, including the acquisition of Rhombus Energy Solutions by BorgWarner in 2022. This acquisition was a significant milestone, showcasing the firm's ability to scale innovative companies to global markets. The firm is led by founder and managing partner Andrée-Lise Méthot, along with a team of experienced partners and venture capitalists. They emphasize long-term collaboration with entrepreneurs, providing both financial support and strategic guidance to help their portfolio companies achieve significant growth and impact.

DAAL Ventures is a venture capital firm headquartered in Saudi Arabia, focusing on early-stage investments in the technology sector, particularly in emerging markets. Founded with the mission to bridge international innovation and the Middle East, DAAL plays a pivotal role in helping startups expand into the GCC region, especially Saudi Arabia. The firm is known for providing not only capital but also strategic guidance and mentorship to its portfolio companies. DAAL leverages its extensive regional network and expertise to support startups in various sectors, including fintech, SaaS, artificial intelligence (AI), Internet of Things (IoT), and big data. DAAL Ventures stands out for its collaborative approach, positioning itself as a partner to the companies it backs. This involves helping entrepreneurs scale their operations globally and connecting them with world-class investors and local partners in the Middle East. The firm has invested in a diverse range of startups, including Pulppo, a Mexican proptech platform, and Paym.es, a fintech company, highlighting its commitment to identifying high-potential tech ventures across different regions​. The firm’s vision is to be a leader in tech-focused venture capital in Saudi Arabia and the broader GCC region. DAAL is committed to fostering growth by offering operational support, business development resources, and access to its network of strategic partners. This positions DAAL Ventures as a key player for startups looking to break into the Middle Eastern market​.

DAG Ventures is a Palo Alto-based growth-stage venture capital firm founded in 2004 by Tom Goodrich and John Cadeddu, who also co-founded Corner Ventures. One of Silicon Valley's most prolific growth investors, DAG has backed 172 companies with an exceptional track record of 130 exits and 5 unicorns. The firm focuses on later-stage investments across IT, life sciences, healthcare, consumer services, and technology, deploying $10 million to $30 million checks predominantly at Series B and C. John J. Cadeddu serves as Founder and Managing Director. DAG's portfolio is a register of consequential technology companies. Notable holdings and exits include Ambarella in semiconductors, Eventbrite in event management, FireEye in cybersecurity, Glassdoor acquired by Recruit Holdings for $1.2 billion, Grubhub in food delivery, Nextdoor in social networking, Wealthfront in robo-advisory, Wix.com in website building, Yelp in local reviews, Zettle acquired by PayPal, and Armo Biosciences in oncology. All of these companies reached IPO, acquisition, or significant secondary liquidity events. DAG's investment approach centers on identifying companies that have already demonstrated product-market fit and are ready to scale, then providing both growth capital and the firm's extensive network of corporate relationships and strategic advisors. The firm leads its positions and partners with management teams through the transition from growth-stage startup to enduring market leader — a phase that demands different skills than early-stage investing and where DAG's track record speaks for itself.

Danone Ventures, the corporate venture arm of Danone, is at the forefront of investing in groundbreaking startups within the food and beverage industry. Notable investments include Farmer's Fridge, Harmless Harvest, and Michel et Augustin, demonstrating their commitment to supporting innovative brands that push the boundaries of health and sustainability. With a strategic focus on early-stage companies, Danone Ventures targets sectors such as plant-based products, sustainable food systems, and personalized nutrition. Their geographic reach spans across North America, Europe, and increasingly into emerging markets, showcasing a global outlook with a local touch. Danone Ventures employs a proactive investment strategy, often taking significant stakes and leading funding rounds. They typically invest between $1M and $10M, providing not just capital but also leveraging Danone's extensive resources to help startups scale. The firm has shown consistent activity, with recent investments in companies like Nature’s Fynd and Ready, Set, Food!, highlighting their commitment to innovation and sustainability. The team at Danone Ventures includes experts like Laurent Marcel and Emmanuel Faber, who bring deep industry knowledge and a passion for transforming the food landscape. Startups looking to partner with Danone Ventures should emphasize their innovative approach and alignment with Danone's mission of bringing health through food to as many people as possible. Being approachable and showcasing strong market potential are key to gaining their interest. Danone Ventures is dedicated to fostering a healthier world through strategic and impactful investments.

Daphni Ventures, based in Paris, was founded in 2016 and focuses on early-stage investments with a European DNA and strong international ambition. The firm aims to support companies that contribute to making the world a better place through innovative and disruptive models, emphasizing social and environmental sustainability. Daphni's investment thesis revolves around empowering founders to create a sustainable future by leveraging deep tech and innovation. The firm has made over 80 investments and has seen multiple successful exits, including Shine.fr, Masteos, and Foxintelligence. Their portfolio includes a wide range of companies such as ZOE, a personalized nutrition platform; Double, a remote executive assistant service; and Masteos, a full-stack real estate agency. They also back companies in sectors like edtech, fintech, and health tech, supporting ventures that focus on the circular economy, upcycling, social inclusion, and the future of work. Daphni operates three main investment vehicles: Purple, Yellow, and Dastore, each focusing on different areas of innovation and sustainability. Their approach involves not only providing capital but also offering operational support and access to a community of experts to facilitate collaboration and knowledge-sharing among their portfolio companies.

DarkMode Ventures is an early-stage venture capital firm founded in 2021 by Amir Shevat, Kat Orekhova, and Rapha Danilo, all of whom are seasoned entrepreneurs with deep experience in developer platforms, AI, and enterprise software. With a fund size of $5 million, DarkMode specializes in writing checks between $100,000 and $200,000, focusing on startups in the developer tools, AI/ML, and modern data stack sectors. Notable investments include Drata, Tabnine, Merge, and Bluesky, with the fund targeting both U.S.-based and international companies, particularly in Israel. DarkMode prides itself on a “by builders for builders” ethos, where they leverage their operational expertise to provide hands-on support to founders. They aim to be more than just a financial backer, offering real-world advice and maintaining a close, transparent relationship with startups. The firm typically does not lead funding rounds but collaborates with other VCs and strategic angels to help startups secure their first significant investments. Their LPs include executives from major tech companies like Meta, Google, and Coinbase, as well as leading institutional investors like Bain Capital and Foundation Capital. DarkMode is known for its fast decision-making process and commitment to founders with a clear vision and strong execution skills. Their focus is on building long-term relationships and backing founders willing to take big risks for transformative outcomes​.

DART Labs & Ventures is a Zurich-based early-stage venture capital firm founded in 2017 by Sophie Lamparter and Arijana Walcott, both serving as Managing Partners, with a satellite office at swissnex San Francisco. The firm invests in European academics, innovators, and early-stage entrepreneurs working on breakthrough technologies for health and climate impact, with a notable 50% diversity factor across its portfolio. DART provides each portfolio company with a tailored 12-month acceleration program designed specifically to help European startups navigate and expand into the US market. DART leads rounds and deploys $200,000 to $300,000 at pre-seed and seed stages. The health portfolio includes Bea Fertility in at-home fertility care, BottNeuro in digital brain health, Impli in implantable bio-sensors, Perivision in AI-powered vision care, Resmonics in remote lung monitoring, Una Health in blood sugar tracking, and Xsensio in on-skin bio-sensors. The climate portfolio spans Fluidsolids in bioplastics, Gaeastar in sustainable cups, Inergio in mini fuel cells, and Orbillion Bio in cultivated meat. Across 15 investments, the firm has recorded 1 exit (VAY, September 2021). A 30-plus-member advisory network spanning Google, Meta, Stanford, ETH Zurich, Daimler, Takeda, and True Ventures provides portfolio companies with access to corporate partners, academic institutions, and top-tier investors. Venture Partner Priska Roesli leads the firm's finance function. DART also operates Vitamin°C, a female-led initiative focused on climate change mitigation.

Day One Capital, founded in 2011, is a venture capital firm based in Budapest, Hungary, focusing on early-stage technology startups primarily in the Central and Eastern European (CEE) region. They are known for their investments in B2B software companies, leveraging the region's strong talent pool to support technology-driven founders. Day One Capital has built a diverse portfolio across various industries, including AI, fintech, and logistics. Notable investments include Turbine AI, which uses simulated cell technology to enhance drug discovery; Webshippy, a logistics and fulfillment service provider; and Volteum, a company aiding electric vehicle fleet management. They have also backed companies like Colossyan, which specializes in generative AI for video editing, and Commsignia, a leader in automotive IoT​. Their typical investment range is from €300k to €1.5 million for seed and Series A rounds. They have been instrumental in helping companies scale globally, providing not only capital but also strategic support and mentorship from their experienced team, which includes former government officials and seasoned investors​​. Day One Capital continues to foster growth and innovation within the CEE region, contributing significantly to the local startup ecosystem and helping companies achieve successful exits, such as AImotive's acquisition by Stellantis and NOW Technologies' acquisition by Sunrise Medical​​.

Day One Ventures, founded by Masha Bucher in 2018, is a dynamic early-stage venture capital firm based in San Francisco. Known for their unique approach, they combine investment with hands-on PR and communication support, setting them apart in the VC landscape. The fund focuses on industries such as fintech, climate and energy, AI, deep tech, consumer products, and enterprise solutions, with a geographic emphasis on North America and Europe. Their portfolio boasts notable investments in companies like DuckDuckGo, Remote, WorldCoin, and Superplastic. Day One Ventures typically invests between $100K and $1M, often leading seed and Series A rounds. They have a strong track record, with 22 exits and several unicorns under their belt, aggregating over $115 billion in value. Masha Bucher, a Forbes 30 Under 30 honoree and former PR executive, leverages her extensive communications background to provide unparalleled support to portfolio companies, from media strategy to investor introductions. The team, including key members like Drake Rehfeld and Tara Harandi-Zadeh, is deeply involved in every step of the startups' journeys, fostering a close-knit community.

DBL Partners, also known as DBL Investors, is a pioneering venture capital firm that integrates financial returns with social, environmental, and economic benefits—a concept they refer to as the "Double Bottom Line." Founded in 2004 and based in San Francisco, DBL Partners has a strong portfolio that includes high-profile companies such as Tesla, SpaceX, SolarCity, and Pandora. Their investments span sectors like clean energy, sustainable products and services, information technology, and healthcare. DBL's investment strategy is rooted in the belief that strong financial performance and positive social impact are interconnected. This approach is evident in their support for companies like Revolution Foods, which provides healthy meals to schools, and Ecologic Brands, which produces environmentally friendly packaging. DBL assists its portfolio companies not only with capital but also by helping them achieve secondary social and environmental goals, such as creating jobs in underserved communities or reducing carbon footprints. Key team members include Nancy Pfund, who has been instrumental in shaping DBL's impact investment strategy. DBL's focus on nurturing the social aspects of their investments has led to successful outcomes, both in terms of market traction and community benefits. For instance, Pandora's decision to locate its headquarters in Oakland helped revitalize the area and create jobs.

DCM Ventures, founded in 1996 and based in Menlo Park, California, is a prominent venture capital firm known for its extensive portfolio and successful investments. With over $4 billion under management, DCM focuses on early-stage technology companies across the U.S., China, and Japan. Notable investments by DCM Ventures include companies like SoFi, Careem, Fortinet, and Matterport. These companies highlight DCM’s diverse investment strategy, spanning fintech, cybersecurity, consumer internet, and enterprise software. The firm has also backed companies like Bill.com and Musical.ly (now TikTok), which have seen significant growth and success​​. DCM Ventures operates with a global perspective, investing in the three largest technology markets: the U.S., China, and Japan. This strategic approach has enabled DCM to deliver strong returns to its limited partners, with a focus on early-stage SaaS, fintech startups, and consumer internet companies. The firm has seen numerous successful exits, with 254 companies in its portfolio going public or being acquired​​. The leadership team at DCM includes co-founders David Chao and Xinhe Lin, who guide the firm’s global investment strategy and operational support to its portfolio companies. For startups looking to connect with DCM Ventures, demonstrating innovative solutions in high-growth sectors such as fintech, AI, and cybersecurity can align well with the firm’s investment focus​.

DCVC (Data Collective Venture Capital) is a deep tech venture capital firm based in Palo Alto, California, founded in 2010 by Matthew Ocko and Michael Driscoll. The firm focuses on investing in groundbreaking technologies that address significant global challenges across various sectors, including artificial intelligence, space, climate, engineering, and more. DCVC manages multiple funds, including DCVC V, which is a $725 million fund aimed at disrupting substantial sectors of the global economy. The firm emphasizes backing startups that employ computational and engineering approaches to solve high-stakes problems. Notable portfolio companies include Pivot Bio, Planet, Zymergen, Atomwise, Rocket Lab, and Recursion Pharmaceuticals, all of which are leaders in their respective industries. DCVC also has a specialized branch, DCVC Bio, co-founded with Dr. John Hamer and Dr. Kiersten Stead, focusing on AI-enabled life sciences platforms. This branch aims to bring new medicines to market and commercialize biological breakthroughs, with companies like AbCellera, Chroma Medicine, and Totus Medicines leading the charge​. The firm’s investment strategy is driven by a belief that venture capital can address urgent global problems profitably and equitably, turning challenges into opportunities while delivering strong returns. DCVC continues to expand its team with experts across various fields to support its growing portfolio and mission​.

De Novo Ventures was a Menlo Park, California-based venture capital firm founded in 2000 by Richard Ferrari and David Mauney, specializing exclusively in medical devices and biotechnology. The firm managed approximately $650 million across three funds, with its largest — De Novo Ventures III LP — reaching $300 million. Over its lifetime, De Novo backed more than 40 companies and led rounds throughout early and growth stages. The portfolio produced a strong exit track record: Pulmonx went public on NASDAQ at a $645 million market capitalization, EBR Systems listed on the ASX in 2021, and AxoGen completed a public offering, alongside 25 acquisitions across the portfolio. Additional companies included EndoGastric Solutions, TRIA Beauty, Benvenue Medical, and Milo. Average checks ranged from $3 million to $50 million, reflecting the capital-intensive nature of medical device development. Richard Ferrari, the managing director, brought over 35 years of medical device entrepreneurship to the partnership, having previously led CardioThoracic Systems to IPO and Cardiovascular Imaging Systems to acquisition by Boston Scientific. De Novo Ventures combined that operational depth with patient capital structured for the long regulatory cycles inherent to life sciences. The firm is now permanently closed; its most recent portfolio activity was the acquisition of TRIA Beauty by CurrentBody in October 2024.

Decent Capital, founded in 2007 by Jason Zeng, co-founder of Tencent, is a prominent venture capital firm with a global presence. The firm focuses on early-stage investments across sectors such as SaaS, consumer internet, frontier tech, and sustainable technology, with investments ranging from pre-seed to Series A stages. Decent Capital’s diverse portfolio includes notable companies like Lime, Cider, and Huizuche. Lime is well-known for its smart scooters and bikes aimed at addressing last-mile transportation issues, while Cider is a direct-to-consumer e-commerce platform for fashion. Huizuche, another significant investment, focuses on car rental services in China. The firm has seen successful exits, such as the acquisition of Oculii and Huizuche, and the IPO of FangDD on NASDAQ in 2019. The firm’s investment strategy emphasizes supporting companies through their growth stages with continued capital and strategic guidance. Decent Capital operates from multiple locations, including offices in Shenzhen, Hong Kong, Singapore, and the United States, ensuring a broad reach and impact across various markets.

Deep Blue Ventures (DBV) is Italy's first deep tech venture capital fund focused on Rome, launched in 2023 and managed by Deep Ocean Capital SGR S.p.A. The fund closed its first tranche at EUR 40.8 million against a EUR 70 million target, backed by cornerstone investors including the European Investment Fund (EIF), CDP Venture Capital SGR, Blue Ocean Finance, and ReItaly21 — a coalition that reflects DBV's ambition to anchor Rome in the European deep tech map. The fund leads at seed stage, with selective Series A participation. DBV deploys EUR 500,000 to EUR 2.5 million per investment, targeting exponential technologies including artificial intelligence, quantum computing, photonics, cybersecurity, synthetic biology, and advanced materials applied to strategic sectors such as aerospace, healthcare, and sustainability. The portfolio of 7 investments — completed within the first 18 months of operation — includes AI4IV in neuromorphic computing, OhmSpace in aerospace, PhotonPath in semiconductor photonics, Genoa Instruments in super-resolution microscopy, and Random Power in quantum randomness. Key institutional partners include Leonardo, the European Space Agency, I3P incubator at Politecnico di Torino, the Italian Institute of Technology, and the National Research Council. DBV is led by Chairman and Co-Founder Emilia Garito, CEO and Co-Founder Domenico Nesci, and Chief Investment Officer Paolo Cellini. The firm operates a Deep Tech Factory Model that combines venture capital with venture building to accelerate the de-risking of breakthrough technologies from Italian and European research institutions into scalable commercial ventures.

Deep Science Ventures (DSV) is a London-based venture studio founded in 2016 that specializes in building science-driven startups across four key sectors: agriculture, computation, climate, and pharmaceuticals. DSV's approach is unique in that it combines scientific knowledge with entrepreneurial expertise to create high-impact ventures from scratch. They partner closely with founder-scientists to tackle some of the world's most pressing challenges, such as reversing global warming, developing curative therapeutics, and advancing computational technologies. DSV's portfolio includes a diverse range of companies, such as Mission Zero Technologies, which focuses on energy-efficient direct air capture of CO2, and Neobe Therapeutics, which is engineering bacteria to improve the efficacy of cancer immunotherapy. These ventures reflect DSV's commitment to creating transformative solutions that are both scientifically rigorous and commercially viable. The firm's model emphasizes de-risking ventures through deep technical and market analysis before significant capital is committed. This methodical approach ensures that the startups they create have a strong foundation for long-term success.

Deepbridge Capital, established in 2010 and headquartered in Chester, UK, focuses on providing growth capital to companies in the technology, life sciences, and renewable energy sectors. Their investment approach emphasizes supporting innovative and high-growth potential companies through various tax-efficient investment opportunities. Deepbridge Capital's portfolio includes a diverse array of companies. Notable investments are in firms like AlgaeCytes, which specializes in producing high-quality EPA oils from algae, and VoxSmart, which provides compliance management solutions for banks. They have also invested in promising startups like Thalia Design Automation, an AI-driven EDA platform, and Ibis Vision, a cloud-based vision testing software for the optical industry. The firm has made 168 investments and has seen 101 exits, showcasing their experience and success in nurturing companies to achieve significant milestones. Deepbridge Capital also supports companies through initiatives such as the Deepbridge Technology Growth EIS Fund and the Deepbridge Innovation SEIS Fund, offering financial backing and strategic guidance to early-stage businesses. The Deepbridge team, led by Managing Partner Ian Warwick, is known for their commitment to fostering innovation and growth across their investment sectors. For more information about their investments and strategic approach, you can visit their official website.

The DeepTech & Climate Fonds (DTCF) is a German venture capital fund aimed at supporting growth-stage startups working on transformative technologies in sectors such as deep tech and climate tech. Established in 2023, the fund has a capital pool of €1 billion, sourced from Germany’s Future Fund and the European Recovery Program. It focuses on companies developing solutions in fields like Industry 4.0, quantum computing, AI, and clean energy technologies. DTCF primarily invests in companies that require long development cycles and substantial capital, providing them with the resources to scale their innovations across Europe. The fund works as an anchor investor, partnering with institutional investors, family offices, and private capital to ensure that these companies can achieve commercial success and contribute to a climate-neutral economy. Led by Dr. Elisabeth Schrey and Tobias Faupel, DTCF has already made notable investments in companies like Membion, which focuses on wastewater recycling, and Cylib, a battery recycling startup. The fund's mission is to drive systemic change by investing in technologies that will reshape industries and contribute to sustainability across the European tech landscape​.

DeepWork Capital, established in 2015 and based in Orlando, Florida, is an early-stage venture capital firm. The firm primarily targets technology and life sciences startups, particularly those in U.S. regions traditionally underserved by venture capital. DeepWork Capital's investment strategy focuses on seed and Series A stage companies, often being the first institutional capital after friends, family, and angel investors. Their portfolio includes a diverse range of companies such as AbFero Pharmaceuticals, acquired by Pharmacosmos, and AireHealth, addressing respiratory challenges. Other notable investments include Astrocyte Pharmaceuticals, developing therapeutics for brain injury, and Genascence, working on gene therapy for musculoskeletal diseases. The firm also supports innovative startups like Nanophotonica, which is pioneering EL-QLED technology, and Homee, which digitizes insurance claims processes. The DeepWork Capital team, including Managing Partners Mitchel Laskey, Ben Patz, and Kathy Chiu, brings a wealth of experience from various industries. The firm emphasizes a hands-on, active engagement approach, supporting entrepreneurs before, during, and after investment. DeepWork Capital's mission is to foster innovation in regions like Florida by providing necessary capital and strategic support to tech-forward founders committed to solving significant societal challenges.

Deerfield Management, a prominent investment firm based in New York City, is dedicated to advancing healthcare through strategic investments, information, and philanthropy. With over $14.6 billion in assets under management, Deerfield maintains a diverse portfolio of more than 200 private and public investments across biotechnology, pharmaceuticals, medical devices, healthcare services, and digital health industries​ . Notable portfolio companies include Graphcore, JFrog, and Netskope. The firm has a strong track record of supporting startups from early stages to mature companies, offering flexible funding models, including equity, debt, and joint ventures. Deerfield’s investment approach is characterized by deep operational support and a robust network of strategic partners and academic collaborations​ ​. Deerfield’s team comprises over 150 experienced professionals with expertise in various sectors of healthcare and finance, ensuring comprehensive support for their portfolio companies. The firm’s initiatives, such as the Deerfield Discovery and Development (3DC) and the Cure Campus, further highlight their commitment to fostering innovation and addressing complex health issues​​. The Deerfield Foundation, part of the firm’s philanthropic efforts, focuses on improving healthcare delivery, particularly for underserved populations, and has invested over $68 million in various health initiatives.

Define Ventures is a premier early-stage venture capital firm, singularly focused on investing in digital health companies. With a keen eye for transformative potential, Define Ventures partners with innovative entrepreneurs to reshape the healthcare landscape. Their portfolio features notable investments such as Blackbird Health, which is revolutionizing pediatric mental health, and Lightship, a pioneer in decentralized clinical trials. Define Ventures operates primarily within the digital health sector, focusing on business models that integrate technology and healthcare to create scalable solutions. Geographically, they concentrate their efforts within the United States, fostering close relationships with startups that promise substantial impact in the national healthcare system. The firm’s strategy centers on leading early-stage funding rounds, including incubation, seed, Series A, and Series B stages. Define Ventures is renowned for their hands-on approach, providing not just capital but also strategic guidance and industry expertise to help their portfolio companies thrive. The team is led by industry veterans like Lynne Chou O'Keefe, the founder and managing partner, whose vision drives the firm's success. Other key members include A.G. Breitenstein and Frank Williams, both of whom bring extensive experience in healthcare and digital innovation. Define Ventures has recently closed $460 million across Fund III and an Opportunities Fund, cementing its position as a significant player in digital health investment.

Defy Ventures, a New York-based venture capital firm founded in 2010 by Catherine Hoke, focuses on early-stage investments and supporting entrepreneurs, particularly those with unconventional backgrounds such as former convicts. The firm is dedicated to fostering entrepreneurship, employment, and character training for its community. Defy's portfolio includes notable companies such as Nautilus Biotechnology, Empower, and Shujinko. They have made significant investments in various sectors, including high tech, business services, and food and agriculture tech. Recent investments include Monitaur, Writ, and Delivery Collective. The firm values authenticity and the tenacity needed to transform bold ideas into lasting companies. Defy Ventures aims to be the partner of choice for today's daring startup founders, helping them become tomorrow's visionary leaders. They emphasize working behind the scenes to amplify the success of their portfolio companies.

Delight Ventures is a Tokyo-based venture capital firm founded in July 2019 by Tomoko Namba, founder and chairperson of DeNA, one of Japan's leading internet companies. Originally spun out as a corporate venture unit with DeNA as its sole limited partner, the firm operates independently with investment decisions made by an autonomous team. Delight manages two funds — Fund I at approximately $100 million and Fund II at JPY 15 billion raised in 2023 — and has built a portfolio of 83 investments across Japan. The firm invests at pre-seed, seed, and Series A stages with average checks around $2 million and leads rounds. Focus sectors span AI, software, fintech, health tech, biotech, and climate tech. Portfolio companies include Matilda, Woodstock, EMLink, FundingBee, and A-SEEDS. Beyond direct investment, Delight operates a Venture Builder program that incubates companies from the ideation stage, often recruiting DeNA employees as founders and leveraging DeNA's business leaders as mentors — a structure unusual among Japanese VCs. A team of approximately 30, including seven partners, executes the firm's dual mandate across Japan and the United States. Managing Partners Tomoko Namba, Dai Watanabe, and Ryo Bando have structured the firm to pursue purely financial returns, ensuring portfolio companies maintain full optionality at exit with no obligation to align with a corporate parent's strategic agenda.

Delin Ventures is a UK-based, mission-driven venture capital firm that focuses on early-stage investments, specializing in two key areas: Life Sciences and the Future of Work & Learning. Established in 2015, the firm backs founders working on breakthrough technologies that can transform healthcare through cell therapies and the future of human work and learning. Delin invests in pre-seed and seed rounds, with typical ticket sizes ranging from €100,000 to €1.5 million, primarily in European startups. In the Life Sciences domain, Delin is committed to advancing cell therapy solutions that can either cure life-threatening diseases or transform them into manageable, chronic conditions. They also invest in the infrastructure necessary for the development and commercialization of these therapies. Notable investments include startups working on innovative therapeutics, medical services, and manufacturing technologies. In the Future of Work & Learning sector, Delin Ventures aims to unlock human potential by investing in technologies that shape the workforce of tomorrow. This includes HR tech, productivity tools, workforce development, and upskilling platforms. They provide hands-on support to founders, leveraging their deep operational expertise and extensive network. The team, led by founder Igor Linshits, includes experts from various industries, ensuring a strong focus on long-term impact. Delin's strategy is centered around making fewer, high-quality investments to ensure that they can offer exceptional support to their portfolio companies, which includes businesses like Fluidic Analytics, Vidsy, and Ori Biotech. The firm is highly selective, providing patient capital and working closely with founders to scale impactful solutions.

Dell Technologies Capital (DTC) is the venture capital investment arm of Dell Technologies, focusing on early-stage investments in the enterprise technology space. Since its inception in 2012, DTC has invested in over 150 companies, helping to propel innovations in data and analytics, cybersecurity, infrastructure, developer tools, and silicon. Their notable portfolio includes industry leaders like DocuSign, MongoDB, and Cylance​. DTC’s investment strategy is to partner with founders from the early stages and provide not only capital but also deep domain expertise and operational support. The firm’s extensive network within Dell Technologies offers startups real customer connections and the opportunity to scale with the backing of a tech giant. Investments typically range from seed to growth stages, with DTC often leading the rounds​. Headquartered in Palo Alto, California, DTC’s team of investors, technologists, and operators work closely with portfolio companies, guiding them from inception to market leadership. This hands-on approach ensures that the startups benefit from strategic insights and operational know-how, positioning them for successful exits​​. Overall, Dell Technologies Capital stands out for its commitment to fostering groundbreaking enterprise technologies and its robust support system for startups aiming to disrupt the tech landscape.

Delphi Ventures, founded in 1988, is a venture capital firm based in San Mateo, California. The firm focuses primarily on life sciences, including biotechnology, medical devices, and healthcare IT. Over the years, Delphi Ventures has made significant contributions to the life sciences industry with over 318 investments and 190 exits. Notable investments by Delphi Ventures include Revance Therapeutics, Senseonics, and PTC Therapeutics. These companies have developed innovative solutions in neurotoxin aesthetics, continuous glucose monitoring, and treatments for rare diseases, respectively. Revance Therapeutics, for instance, is now a public company with significant revenue, reflecting Delphi Ventures' ability to identify and nurture high-potential startups. Delphi Ventures' investment strategy is centered on early and growth-stage investments, with a focus on supporting pioneering technologies and therapies. The firm has a strong track record of successful exits, including companies that have gone public such as EBR Systems and Senseonics, as well as several notable acquisitions like Seattle Genetics and Acclarent. The team at Delphi Ventures is led by experienced professionals such as Deepa Pakianathan, Douglas Roeder, and founder James Bochnowski. Their expertise and deep industry knowledge play a critical role in guiding portfolio companies toward successful growth and market leadership.

Demeter, a major European player in venture capital, private equity, and infrastructure, focuses on investments that drive the energy and ecological transition. Founded in 2005, Demeter manages €1.3 billion across its funds and has completed over 230 investments. The firm targets innovative startups, SMEs, and infrastructure projects, offering investments ranging from €1 million to €30 million. Notable investments include McPhy Energy, which specializes in hydrogen production, storage, and distribution technologies, and Ynsect, which produces environmentally friendly insect-based products. Demeter also supports companies like Sunna Design, which develops solar LED lighting solutions, and Sweetch Energy, a renewable energy firm focusing on osmotic energy. One of Demeter's significant initiatives is the recent launch of a €500 million fund in collaboration with EIT InnoEnergy. This fund aims to develop a resilient and diverse battery raw material supply chain for Europe, addressing the continent's growing demand for batteries and supporting the European Battery Alliance's goals. Demeter's investment strategy is driven by a commitment to sustainability, evident in their support for green projects like H2 Green Steel, the world's first integrated large-scale green steel plant. The firm's dedication to environmental responsibility is further reflected in their involvement in initiatives like the Climate Dividends program, which promotes sustainability across their portfolio companies.

Dentsu Ventures is the corporate venture capital arm of Dentsu Group, one of the world's largest advertising and marketing conglomerates. Founded in April 2015 and headquartered in Tokyo, Japan, the firm operates two funds totaling 20 billion yen (approximately $134 million): Global Fund I covering 2015 to 2025 and Fund II launched in 2021 with a ten-year life. Managing Partner Kotaro Sasamoto leads a team that includes General Partners Daiji Horibe, Kevin Hasegawa, and Daisuke Takemori. With 65 investments across the US, Europe, and Asia-Pacific, Dentsu Ventures backs companies from Seed through late stage in AI, advertising and marketing technology, media and entertainment, biotech, data analytics, and VR/AR. The portfolio has produced three unicorns, two IPOs, and 12 acquisitions. Notable investments include Mysten Labs (blockchain), GRAIL (cancer detection, acquired by Illumina), Twist Bioscience (synthetic biology, IPO), Kognitos (enterprise AI automation), and Skyflow (data privacy). Dentsu Ventures differentiates from independent VCs by offering portfolio companies direct access to Dentsu Group's global marketing capabilities, client relationships, and co-creation resources. Startups gain the dual benefit of financial backing and commercial acceleration through one of the world's most extensive advertising networks, making the firm particularly valuable to companies building in consumer-facing and enterprise software categories.

Derayah Ventures is a Saudi-based venture capital firm that invests in early to growth-stage startups across the MENA region. Launched in 2019, the firm manages a $30 million fund focused on technology-driven businesses, particularly in sectors such as SaaS, fintech, eCommerce, artificial intelligence, Internet of Things (IoT), and marketplace platforms. Derayah primarily backs companies that are either disrupting traditional industries or organizing them through innovative solutions. The firm’s investment philosophy centers on supporting scalable startups with high growth potential and strong teams. Derayah Venture Capital provides not just financial backing but also strategic guidance to help companies expand within the MENA region, especially into Saudi Arabia. The fund focuses on post-seed, pre-Series A, and Series A stages, enabling startups to access critical capital during their early development phases. Led by a team of experienced investors, including Chairman Faris Ibrahim AlRashed, Derayah aims to build tomorrow's market leaders through a combination of capital, industry expertise, and strong local networks.

Detroit Venture Partners (DVP), founded in 2010 by Dan Gilbert, is a venture capital firm committed to backing early-stage tech startups that aim to drive innovation and economic growth. Based in Detroit, DVP is part of the broader Rock Family of Companies, which includes Rocket Companies, Bedrock Detroit, and the Cleveland Cavaliers. This extensive network enables DVP to offer its portfolio companies not only financial backing but also strategic partnerships and resources to help them scale effectively. DVP focuses on investing in startups that embody creativity, grit, and passion. They have a strong emphasis on companies in the technology sector, including fintech, SaaS, and logistics. Some of their notable portfolio companies include StockX, Livegistics, 100 Thieves, and CoverTree. By fostering innovation, DVP contributes to Detroit’s entrepreneurial ecosystem, helping to rejuvenate the city’s long history of industrial innovation. In addition to their investment activities, DVP runs a Summer Fellowship program that offers MBA and undergraduate students hands-on experience in venture capital and early-stage startups.

Dexcel Pharma is the largest private pharmaceutical company in Israel, renowned for its extensive portfolio of branded and generic drugs. Founded in 1968, the company has grown into a global player, with state-of-the-art R&D and manufacturing facilities that support the development and commercialization of innovative and cost-effective pharmaceutical products. Dexcel's product portfolio spans across various therapeutic areas, including small molecules, biologics, and RNA-based therapies. The company is committed to advancing science through substantial investments in R&D, particularly in cutting-edge fields like siRNA therapeutics and oligonucleotides. Their innovation initiatives include the creation of specialized entities like Dexoligo Therapeutics, which focuses on RNA-based medicines, and Clexio Biosciences, which develops treatments for neurological and psychiatric conditions. With over 1,200 employees and a strong presence in key markets like the United States, Germany, and the UK, Dexcel manufactures over 5 billion oral-solid dosages annually. The company maintains a reputation for quality, with its facilities meeting global standards and holding approvals from regulatory bodies like the FDA and EMA.

DG Daiwa Ventures, a Tokyo-based venture capital firm founded in 2016, is a joint venture between Digital Garage and Daiwa Securities Group. The fund focuses on early-stage investments in cutting-edge technologies, such as blockchain, artificial intelligence (AI), cybersecurity, biohealth, and extended reality (xR). DG Daiwa Ventures operates globally, with a special emphasis on startups in Japan and the broader Asia-Pacific region. The firm manages two main funds: DG Lab Fund I and DG Lab Fund II, which collectively manage over 20 billion yen. These funds target high-potential tech startups by leveraging the combined expertise and incubation capabilities of both Digital Garage and Daiwa Securities. DG Daiwa Ventures has a track record of nurturing successful startups, such as Goodpatch and Akili Interactive Labs, which have gained recognition for their innovative products. DG Daiwa is known for supporting its portfolio companies with strategic resources and helping them scale through partnerships, additional fundraising, and IPO support. The firm aims to identify companies that can drive technological advancements and create substantial returns for investors through a global network of partners and later-stage investors.

DHVC, founded in 2013 by Shoucheng Zhang, is a venture capital firm based in Palo Alto, California. The firm focuses on early-stage investments across several sectors, including enterprise, consumer, fintech, and healthcare. Over the years, DHVC has built a substantial portfolio, investing in over 267 companies with 75 successful exits​. DHVC has also seen significant exits with companies like Wish Shopping, Qeexo, and Namocell, indicating their strong presence in the tech investment space. The firm’s investment strategy involves participating in a mix of seed, early-stage, and later-stage funding rounds, often co-investing with other prominent venture capital firms​. The DHVC team, led by key members such as Kevin Ding and Judy Yan, brings a wealth of experience and a global perspective to their investment approach. The firm’s operations are split between the United States and China, allowing them to leverage opportunities across major innovation hubs​.

Diamond Capital is a venture capital firm based in Taiwan, primarily focusing on investments in the biotechnology, medical, and high-tech sectors. Established in 2013, the firm has built a strong reputation for nurturing innovative companies that are driving advancements in healthcare, new drug development, high-end medical equipment, and innovative medical services. Diamond Capital is known for its strategic investments that span early to growth-stage companies, particularly those operating in Asia. The firm is particularly noted for its involvement in the biotechnology sector, where it has been instrumental in supporting startups that have gone on to achieve significant milestones, including public listings. Diamond Capital's strategy involves not only providing capital but also leveraging its extensive network and expertise to guide companies through the complexities of scaling and entering global markets. This approach has made it a key player in Taiwan’s venture capital landscape. In 2023, Diamond Capital made headlines by becoming the first biotech venture capital firm to list on the Taiwan Stock Exchange, further enhancing its visibility and credibility on the international stage. The firm's portfolio includes a diverse array of companies, from cutting-edge biotech firms to innovative medical device manufacturers, all of which are united by their potential to make significant contributions to their respective fields.

DIC Corporation operates a Corporate Venture Capital (CVC) unit that focuses on strategic investments aligned with their core mission of sustainable innovation. Founded as a global leader in fine chemicals, DIC leverages its venture capital arm to support startups that bring new, disruptive technologies in areas like biomanufacturing, advanced materials, and industrial IT. Their investment strategy aims to complement their existing businesses in sectors such as color science, healthcare, and packaging. Recent notable investments include funding Debut Biotechnology, a California-based company specializing in sustainable biomanufacturing. This partnership allows DIC to accelerate the development of bio-based materials, particularly natural pigments for cosmetics and nutrition, aligning with their long-term vision of sustainability under the DIC Vision 2030 plan. DIC's CVC activities also extend to partnerships with other venture funds, such as their collaboration with Emerald Technology Ventures, which focuses on industrial innovation in clean technology. DIC’s strategic approach to venture investing helps them explore new markets while enhancing their capabilities in sustainable products, driving innovation across their global network of over 190 companies.

DCP Capital is a private equity firm based in Beijing, China, founded in 2017 by Julian Wolhardt and David Liu. The firm focuses on investments in companies operating in sectors such as healthcare devices, semiconductors, commercial services, agriculture, and manufacturing across Mainland China, Hong Kong, Macau, and Taiwan. Notable investments by DCP Capital include Jamieson Wellness, a leading consumer health brand; Mengniu Dairy, one of China’s largest dairy producers; and 51job, a major recruitment website in China, which was acquired for $3.8 billion. The firm has also invested in innovative companies like Broncus Medical, Venus MedTech, and Fenbi, which focuses on education and training services. DCP Capital manages assets of over $2.5 billion, having recently completed the first close of their second China fund. This fund aims to invest in early and growth-stage companies, furthering their mission to support transformative businesses in the region.

Digitalis Ventures is a venture capital firm established in 2016, focused on investing in innovative solutions within the realms of human and animal health. Headquartered in New York, with offices in Boston, Los Angeles, San Diego, San Francisco, and Gainesville, the firm leverages deep technical, financial, and domain expertise to support early-stage companies. Digitalis Ventures’ portfolio includes companies like Expressable, Elegen, and Alterome Therapeutics, reflecting their interest in biotechnology, health technologies, and services. Notable exits include Scout Bio and PetMedix. The firm typically leads investment rounds, providing substantial capital and strategic guidance to help startups scale. The investment strategy centers around life sciences, health technologies, and animal health. They invest in companies developing breakthrough technologies in therapeutics, diagnostics, and tools that improve healthcare access, outcomes, and efficiency. Their Companion Fund specifically focuses on advancing animal health. Key team members include founder Geoffrey Smith and partners such as Amit Bansal and Drew Taylor, who bring extensive experience in venture investing and health technologies.

firm focuses on investing in early-stage companies within the digital health sector, aiming to address significant challenges and inefficiencies in healthcare. Their investment strategy centers on data-driven technologies that can revolutionize healthcare and improve patient outcomes through innovative solutions in personalized medicine, data analytics, and digital therapeutics. DigiTx Partners is notable for backing companies like Eko, which develops diagnostic devices for heart and lung diseases, and Rune Labs, which focuses on precision neurology through software and data analytics. Their portfolio also includes Cleerly, specializing in cardiovascular disease diagnostics, and Savonix, which offers cognitive function management systems. The firm was created as a joint venture between Astellas Pharma and MPM Capital, and it raised $75 million for its Rx Digital Fund in 2018. This fund supports seed and Series A-stage companies that are developing healthcare and life sciences technology utilizing data​. Key team members include Managing Director David Kim, MD, and Partner & Principal Miraj Sanghvi, who bring substantial expertise in healthcare and investment management.

Dimension Capital is an early-stage venture capital firm founded in 2022 by industry veterans from Lux Capital and Obvious Ventures. With a focus on the intersection of biotechnology, life sciences, and technology, the firm operates a $350 million fund aimed at digitizing the biotech sector. Their mission is to break down the traditional silos separating technology and life sciences, creating new synergies between fields like drug discovery and artificial intelligence. Dimension invests in startups that leverage technology to drive advancements in biotech, such as Enveda Biosciences and Kaleidoscope Bio. The firm targets transformative companies in sectors including AI-driven drug discovery, machine learning applications in healthcare, and advanced manufacturing. Led by Adam Goulburn, Zavain Dar, and Nan Li, Dimension emphasizes long-term partnerships with founders, providing both capital and strategic guidance. They are particularly interested in companies at the forefront of merging biology with computational technologies, a space they believe is critical to the future of medicine​. Based in New York and San Francisco, Dimension is well-positioned in two key innovation hubs, giving it access to cutting-edge talent and startups that are redefining the biotech landscape​.

Divergent Capital is a New York-based venture capital firm founded in 2020 by Katie Shea and Lucy Wang. The fund focuses on pre-seed investments, typically writing checks between $250,000 and $750,000. Divergent Capital aims to back 20-25 companies, emphasizing high-conviction investments with deep engagement in sectors like AI, machine learning, robotics, biotech, logistics, and digital health. The firm is known for investing in founders with innovative technologies and unique customer insights, often those outside the traditional Silicon Valley circles. Divergent takes a hands-on approach with its portfolio companies, offering strategic guidance on product development, go-to-market strategies, and scaling. They prefer working with founders who have a deep personal connection to the problem they are solving, focusing on practical, product-driven growth rather than market size alone. Notable investments include companies like Hoop, Motif Neurotech, and Ceragen, spanning industries from productivity software to biotechnology.

DN Capital, founded in 2000, is a global early-stage venture capital firm with offices in London, Berlin, and San Francisco. They focus on Seed, Series A, and select Series B opportunities across Europe and North America. The firm specializes in sectors such as fintech, SaaS, digital media, marketplaces, and consumer internet. Some of DN Capital's notable investments include Shazam, Auto1, OLX, Purplebricks, and GoStudent. These investments showcase DN Capital's knack for identifying and supporting companies that can scale globally. They have managed over $1 billion in assets and achieved numerous successful exits, including acquisitions by major corporations such as Apple (Shazam) and Oracle (Endeca)​. The firm is led by founders Nenad Marovac and Steve Schlenker, who bring deep entrepreneurial and financial expertise. DN Capital emphasizes a hands-on approach, providing portfolio companies with strategic guidance, business development opportunities, and extensive network connections. Their commitment to openness and integrity, combined with rigorous investment practices, makes them a strong partner for ambitious entrepreneurs

DNS Capital is the investment office for Gigi Pritzker and her husband Michael Pucker, based in Chicago. Founded in 2014, DNS Capital invests across various stages and industries, emphasizing long-term partnerships and strategic growth. The firm has a diverse portfolio with significant investments in technology, healthcare, and industrial sectors. Notable investments include Hero Bread, which focuses on producing low-carb bakery products; IMIDomics, a biotech company working on therapeutics for immune-mediated inflammatory diseases; and Jetti Resources, which has developed a novel technology for metal extraction from ores. Other key investments include Recogni, a company specializing in high-performance computer chips for autonomous vehicles, and PayNearMe, a platform enhancing payment experiences for businesses and their customers​​. DNS Capital's approach combines financial support with strategic guidance, leveraging the deep expertise of its leadership team. They focus on building strong relationships with business owners and management teams to drive sustainable growth and innovation across their portfolio companies​.

Dolby Family Ventures is a San Francisco-based venture capital firm founded in 2014 by David Dolby, investing in early-stage companies tackling frontier science and engineering challenges. Unaffiliated with Dolby Laboratories, the firm manages approximately $196 million in assets under management. The 16-person team is led by David Dolby as CEO, Senior Managing Director Pascal Levensohn, and Managing Director Andrew Krowne, supported by a distinguished Scientific Advisory Board. With 106 investments and a strong exit track record of 6 IPOs and 17 acquisitions, Dolby Family Ventures leads rounds across pre-seed, seed, and Series A with checks from $1 million to $25 million. The five core verticals are precision neuroscience (neurodegeneration, psychiatry, neurotech), life sciences platforms (regenerative medicine, computational biology), climate tech, aerospace, and digital deep tech. Portfolio companies include Motif Neurotech, Therini Bio, Ursa Major Technologies, Twelve, Paradromics, Bionaut Labs, and DigiLens. IPO exits include Athira Pharma, Eargo, Cognition Therapeutics, and Tempo Automation; acquisition exits include August (by Assa Abloy), Wickr (by Amazon), and Eyefluence (by Google). The firm takes a long-term collaborative approach, partnering with best-in-class innovators and syndicate partners to build transformative technology companies. Its willingness to back science-forward ventures at the earliest stages — often where commercial validation is years away — and the depth of the Scientific Advisory Board distinguish DFV from generalist firms operating across the same broad technology sectors.

Domain Capital Group, founded in 1985, specializes in biotechnology investments, managing a substantial $2.8 billion in assets. They have funded 194 companies in the biopharma, medical device, and diagnostic sectors, resulting in 90 IPOs and 110 M&A events. Notable companies in their portfolio include Zipline, GitLab, and DigitalOcean. Domain Capital’s strategy focuses on long-term partnerships and a diversified asset approach, investing in real estate, natural resources, media, entertainment, technology, and special situations to achieve stable, cash-on-cash returns. They operate globally with a team led by seasoned partners like James Blair and Brian Halak. Their investment process involves rigorous due diligence, strategic transaction structuring, and active asset management to ensure value creation and capital preservation. Domain Capital typically engages in growth and late-stage investments, leveraging their extensive industry experience and strong relationships to source and manage deals effectively. The firm’s hands-on approach includes personalized investor engagement, aiming to meet specific investment goals such as targeted returns and risk mitigation. This comprehensive strategy positions Domain Capital as a trusted partner for public and private pension plans, corporations, foundations, endowments, and high-net-worth individuals.

Dorm Room Fund (DRF), founded in 2012 by Josh Kopelman under the auspices of First Round Capital, is a venture capital firm that focuses on investing in student-run startups. Headquartered in Cambridge, Massachusetts, DRF has made over 400 investments and has achieved 145 exits. Notable exits include MetaMap, DiscreetAI, WorkerSense, and ScienceIO. DRF’s mission is to support student founders by providing access to a powerful investor network, world-class mentors, and essential capital to accelerate their growth. The fund has supported over 300 companies led by student founders, including prominent names like Athelas and WellTheory. Dorm Room Fund is dedicated to promoting diversity, equity, and inclusion within the venture capital industry. Nearly 80% of their alumni go on to become founders or venture capitalists themselves. The fund has created initiatives like the Blueprint Project and the Female Founder Track to empower underrepresented students. The investment team at DRF consists of student partners who bring unique insights into the next wave of groundbreaking companies. This model allows them to identify promising startups that might be overlooked by traditional investors.

Dow Venture Capital, a corporate venture arm of Dow Inc., focuses on strategic investments that align with Dow's broader goals of sustainability and innovation. Established in 1994, the unit is headquartered in Midland, Michigan, and targets a range of sectors including clean technology, advanced materials, recycling, and healthcare. Their investments often seek to advance circular economy solutions, such as their partnerships with companies like Plastogaz, which aims to simplify plastic recycling processes through advanced catalytic technology, and Mura Technology, which focuses on chemical recycling for hard-to-recycle plastics. Dow Venture Capital also collaborates with companies in the fields of renewable energy, water treatment, and sustainable agriculture, demonstrating their commitment to tackling global environmental challenges. With a presence across North America, Europe, and Asia, their approach blends Dow’s extensive materials science expertise with innovative startup technologies, facilitating solutions that can scale globally. Dow's focus on recycling has led to investments that aim to close the loop on plastic waste, ensuring materials can be reused sustainably​. Overall, Dow Venture Capital plays a key role in Dow’s strategic direction by supporting startups that drive growth and value, particularly in areas that complement their sustainability mission and core business sectors.

Downing LLP is a UK-based investment management firm that emphasizes sustainable and impactful investments across various sectors. Established in 1986, Downing manages around £2 billion in assets, offering a diverse range of investment strategies. It has built a reputation for responsible investing, holding a B Corp certification, which underscores its commitment to balancing profit with social and environmental responsibility. Downing Ventures, a division of Downing LLP, focuses on early to growth-stage technology companies. Their investment portfolio spans sectors including healthcare, clean technology, and software, with a preference for businesses that integrate sustainability and innovative solutions. Recent initiatives include the appointment of Dr. Nigel Pitchford as Head of Healthcare Ventures, reflecting their strategic focus on med-tech and life sciences. This division has supported over 20 healthcare companies, deploying more than £36 million since 2014. In addition to venture capital, Downing also invests in renewable energy projects, infrastructure, and property finance. They operate the Downing Renewables & Infrastructure Trust (DORE), which funds solar, wind, and energy storage projects across the UK and Northern Europe. Through these ventures, Downing aims to deliver stable returns while promoting environmental sustainability​.